A cGAS-independent STING/IRF7 pathway mediates the immunogenicity of DNA vaccines

Journal of Immunology

Volumn 196, Issue 1, 2016, Pages 310-316

  Suschak, John J ^a   Wang, Shixia ^a   Fitzgerald, Katherine A ^a   Lu, Shan ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC GMP; CYCLIC GMP AMP SYNTHASE; DNA VACCINE; INTERFERON REGULATORY FACTOR 3; INTERFERON REGULATORY FACTOR 7; UNCLASSIFIED DRUG; IRF3 PROTEIN, MOUSE; IRF7 PROTEIN, MOUSE; MB21D1 PROTEIN, MOUSE; MEMBRANE PROTEIN; MPYS PROTEIN, MOUSE; NUCLEOTIDYLTRANSFERASE;

ADAPTIVE IMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; B LYMPHOCYTE; CONTROLLED STUDY; DNA IMMUNIZATION; IMMUNOGENICITY; IN VIVO STUDY; INNATE IMMUNITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; T LYMPHOCYTE; ANIMAL; C57BL MOUSE; CELL CULTURE; GENETICS; IMMUNOLOGY; KNOCKOUT MOUSE; METABOLISM;

ANIMALS; B-LYMPHOCYTES; CELLS, CULTURED; IMMUNITY, INNATE; INTERFERON REGULATORY FACTOR-3; INTERFERON REGULATORY FACTOR-7; MEMBRANE PROTEINS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NUCLEOTIDYLTRANSFERASES; SIGNAL TRANSDUCTION; T-LYMPHOCYTES; VACCINES, DNA;

EID: 84953284810     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1501836     Document Type: Article

References (45)

1. Cann, A. J., G. Stanway, P. J. Hughes, P. D. Minor, D. M. Evans, G. C. Schild, and J. W. Almond. 1984. Reversion to neurovirulence of the live-attenuated Sabin type 3 oral poliovirus vaccine. Nucleic Acids Res. 12: 7787-7792.
2. Tang, D. C., M. DeVit, and S. A. Johnston. 1992. Genetic immunization is a simple method for eliciting an immune response. Nature 356: 152-154.
3. Wolff, J. A., R. W. Malone, P. Williams, W. Chong, G. Acsadi, A. Jani, and P. L. Felgner. 1990. Direct gene transfer into mouse muscle in vivo. Science 247: 1465-1468.
4. Ulmer, J. B., J. J. Donnelly, S. E. Parker, G. H. Rhodes, P. L. Felgner, V. J. Dwarki, S. H. Gromkowski, R. R. Deck, C. M. DeWitt, A. Friedman, et al. 1993. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 259: 1745-1749.
5. Fuller, D. H., and J. R. Haynes. 1994. A qualitative progression in HIV type 1 glycoprotein 120-specific cytotoxic cellular and humoral immune responses in mice receiving a DNA-based glycoprotein 120 vaccine. AIDS Res. Hum. Retroviruses 10: 1433-1441.
6. Donnelly, J. J., D. Martinez, K. U. Jansen, R. W. Ellis, D. L. Montgomery, and M. A. Liu. 1996. Protection against papillomavirus with a polynucleotide vaccine. J. Infect. Dis. 173: 314-320.
7. Kennedy, J. S., M. Co, S. Green, K. Longtine, J. Longtine, M. A. O'Neill, J. P. Adams, A. L. Rothman, Q. Yu, R. Johnson-Leva, et al. 2008. The safety and tolerability of an HIV-1 DNA prime-protein boost vaccine (DP6-001) in healthy adult volunteers. Vaccine 26: 4420-4424.
8. Wang, S., J. S. Kennedy, K.West, D. C. Montefiori, S. Coley, J. Lawrence, S. Shen, S. Green, A. L. Rothman, F. A. Ennis, et al. 2008. Cross-subtype antibody and cellular immune responses induced by a polyvalent DNA prime-protein boost HIV- 1 vaccine in healthy human volunteers. Vaccine 26: 3947-3957.
9. Khurana, S., J. Wu, M. Dimitrova, L. R. King, J. Manischewitz, B. S. Graham, J. E. Ledgerwood, and H. Golding. 2013. DNA priming prior to inactivated influenza A(H5N1) vaccination expands the antibody epitope repertoire and increases affinity maturation in a boost-interval-dependent manner in adults. J. Infect. Dis. 208: 413-417.
10. Ledgerwood, J. E., Z. Hu, I. J. Gordon, G. Yamshchikov, M. E. Enama, S. Plummer, R. Bailer, M. B. Pearce, T. M. Tumpey, R. A. Koup, et al; VRC 304 and VRC 305 Study Teams. 2012. Influenza virus H5 DNA vaccination is immunogenic by intramuscular and intradermal routes in humans. Clin. Vaccine Immunol. 19: 1792-1797.
11. Ledgerwood, J. E., C. J. Wei, Z. Hu, I. J. Gordon, M. E. Enama, C. S. Hendel, P. M. McTamney, M. B. Pearce, H. M. Yassine, J. C. Boyington, et al; VRC 306 Study Team. 2011. DNA priming and influenza vaccine immunogenicity: two phase 1 open label randomised clinical trials. Lancet Infect. Dis. 11: 916-924.
12. Lu, S. 2009. Heterologous prime-boost vaccination. Curr. Opin. Immunol. 21: 346-351.
13. Vaine, M., S. Wang, E. T. Crooks, P. Jiang, D. C. Montefiori, J. Binley, and S. Lu. 2008. Improved induction of antibodies against key neutralizing epitopes by human immunodeficiency virus type 1 gp120 DNA prime-protein boost vaccination compared to gp120 protein-only vaccination. J. Virol. 82: 7369-7378.
14. Vaine, M., S. Wang, A. Hackett, J. Arthos, and S. Lu. 2010. Antibody responses elicited through homologous or heterologous prime-boost DNA and protein vaccinations differ in functional activity and avidity. Vaccine 28: 2999-3007.
15. Wang, S., A. Hackett, N. Jia, C. Zhang, L. Zhang, C. Parker, A. Zhou, J. Li, W. C. Cao, Z. Huang, et al. 2011. Polyvalent DNA vaccines expressing HA antigens of H5N1 influenza viruses with an optimized leader sequence elicit cross-protective antibody responses. PLoS One 6: e28757.
16. Wang, S., C. Parker, J. Taaffe, A. Solórzano, A. García-Sastre, and S. Lu. 2008. Heterologous HA DNA vaccine prime-inactivated influenza vaccine boost is more effective than using DNA or inactivated vaccine alone in eliciting antibody responses against H1 or H3 serotype influenza viruses. Vaccine 26: 3626-3633.
17. Pal, R., Q. Yu, S.Wang, V. S. Kalyanaraman, B. C. Nair, L. Hudacik, S. Whitney, T. Keen, C. L. Hung, L. Hocker, et al. 2006. Definitive toxicology and biodistribution study of a polyvalent DNA prime/protein boost human immunodeficiency virus type 1 (HIV-1) vaccine in rabbits. Vaccine 24: 1225-1234.
18. Suguitan, A. L., Jr., X. Cheng, W. Wang, S. Wang, H. Jin, and S. Lu. 2011. Influenza H5 hemagglutinin DNA primes the antibody response elicited by the live attenuated influenza A/Vietnam/1203/2004 vaccine in ferrets. PLoS One 6: e21942.
19. Lu, S. 2006. Combination DNA plus protein HIV vaccines. Springer Semin. Immunopathol. 28: 255-265.
20. Wang, S., R. Pal, J. R. Mascola, T. H. Chou, I. Mboudjeka, S. Shen, Q. Liu, S. Whitney, T. Keen, B. C. Nair, et al. 2006. Polyvalent HIV-1 Env vaccine formulations delivered by the DNA priming plus protein boosting approach are effective in generating neutralizing antibodies against primary human immunodeficiency virus type 1 isolates from subtypes A, B, C, D and E. Virology 350: 34-47.
21. Vaine, M., S. Wang, Q. Liu, J. Arthos, D. Montefiori, P. Goepfert, M. J. McElrath, and S. Lu. 2010. Profiles of human serum antibody responses elicited by three leading HIV vaccines focusing on the induction of Env-specific antibodies. PLoS One 5: e13916.
22. Hollister, K., Y. Chen, S. Wang, H Wu, A. Mondal, N. Clegg, S. Lu, and A. Dent. 2014. The role of follicular helper T cells and the germinal center in HIV-1 gp120 DNA prime and gp120 protein boost vaccination. Hum. Vaccin. Immunother. 10: 1985-1992. doi:10.4161
23. Tudor, D., C. Dubuquoy, V. Gaboriau, F. Lefèvre, B. Charley, and S. Riffault. 2005. TLR9 pathway is involved in adjuvant effects of plasmid DNA-based vaccines. Vaccine 23: 1258-1264.
24. Ishikawa, H., Z. Ma, and G. N. Barber. 2009. STING regulates intracellular DNAmediated, type I interferon-dependent innate immunity. Nature 461: 788-792.
25. Unterholzner, L., S. E. Keating, M. Baran, K. A. Horan, S. B. Jensen, S. Sharma, C. M. Sirois, T. Jin, E. Latz, T. S. Xiao, et al. 2010. IFI16 is an innate immune sensor for intracellular DNA. Nat. Immunol. 11: 997-1004.
26. Hornung, V., A. Ablasser, M. Charrel-Dennis, F. Bauernfeind, G. Horvath, D. R. Caffrey, E. Latz, and K. A. Fitzgerald. 2009. AIM2 recognizes cytosolic dsDNA and forms a caspase-1-activating inflammasome with ASC. Nature 458: 514-518.
27. Li, X. D., J. Wu, D. Gao, H. Wang, L. Sun, and Z. J. Chen. 2013. Pivotal roles of cGAS-cGAMP signaling in antiviral defense and immune adjuvant effects. Science 341: 1390-1394.
28. Babiuk, S., N. Mookherjee, R. Pontarollo, P. Griebel, S. van Drunen Littel-van den Hurk, R. Hecker, and L. Babiuk. 2004. TLR92/2 and TLR9+/+ mice display similar immune responses to a DNA vaccine. Immunology 113: 114-120.
29. Ishii, K. J., T. Kawagoe, S. Koyama, K. Matsui, H. Kumar, T. Kawai, S. Uematsu, O. Takeuchi, F. Takeshita, C. Coban, and S. Akira. 2008. TANKbinding kinase-1 delineates innate and adaptive immune responses to DNA vaccines. Nature 451: 725-729.
30. Suschak, J. J., S. Wang, K. A. Fitzgerald, and S. Lu. 2015. Identification of Aim2 as a sensor for DNA vaccines. J. Immunol. 194: 630-636.
31. Ishii, K. J., C. Coban, H. Kato, K. Takahashi, Y. Torii, F. Takeshita, H. Ludwig, G. Sutter, K. Suzuki, H. Hemmi, et al. 2006. A Toll-like receptor-independent antiviral response induced by double-stranded B-form DNA. Nat. Immunol. 7: 40-48.
32. Tudor, D., S. Riffault, C. Carrat, F. Lefèvre, M. Bernoin, and B. Charley. 2001. Type I IFN modulates the immune response induced by DNA vaccination to pseudorabies virus glycoprotein C. Virology 286: 197-205.
33. Shirota, H., L. Petrenko, T. Hattori, and D. M. Klinman. 2009. Contribution of IRF-3 mediated IFNb production to DNA vaccine dependent cellular immune responses. Vaccine 27: 2144-2149.
34. Schoggins, J. W., D. A. MacDuff, N. Imanaka, M. D. Gainey, B. Shrestha, J. L. Eitson, K. B. Mar, R. B. Richardson, A. V. Ratushny, V. Litvak, et al. 2014. Pan-viral specificity of IFN-induced genes reveals new roles for cGAS in innate immunity. Nature 505: 691-695.
35. Roberts, Z. J., N. Goutagny, P. Y. Perera, H. Kato, H. Kumar, T. Kawai, S. Akira, R. Savan, D. van Echo, K. A. Fitzgerald, et al. 2007. The chemotherapeutic agent DMXAA potently and specifically activates the TBK1-IRF-3 signaling axis. J. Exp. Med. 204: 1559-1569.
36. Wang, S., J. Taaffe, C. Parker, A. Solórzano, H. Cao, A. García-Sastre, and S. Lu. 2006. Hemagglutinin (HA) proteins from H1 and H3 serotypes of influenza A viruses require different antigen designs for the induction of optimal protective antibody responses as studied by codon-optimized HA DNA vaccines. J. Virol. 80: 11628-11637.
37. Zhang, L., N. Jia, J. Li, Y. Han, W. Cao, S. Wang, Z. Huang, and S. Lu. 2014. Optimal designs of an HA-based DNA vaccine against H7 subtype influenza viruses. Hum. Vaccin. Immunother. 10: 1949-1958.
38. Almansour, I., H. Chen, S. Wang, and S. Lu. 2013. Cross reactivity of serum antibody responses elicited by DNA vaccines expressing HA antigens from H1N1 subtype influenza vaccines in the past 30 years. Hum. Vaccin. Immunother. 9: 2049-2059.
39. Honda, K., H. Yanai, H. Negishi, M. Asagiri, M. Sato, T. Mizutani, N. Shimada, Y. Ohba, A. Takaoka, N. Yoshida, and T. Taniguchi. 2005. IRF-7 is the master regulator of type-I interferon-dependent immune responses. Nature 434: 772-777.
40. Shirota, H., L. Petrenko, C. Hong, and D. M. Klinman. 2007. Potential of transfected muscle cells to contribute to DNA vaccine immunogenicity. J. Immunol. 179: 329-336.
41. Oganesyan, G., S. K. Saha, E. M. Pietras, B. Guo, A. K. Miyahira, B. Zarnegar, and G. Cheng. 2008. IRF3-dependent type I interferon response in B cells regulates CpG-mediated antibody production. J. Biol. Chem. 283: 802-808.
42. Honda, K., Y. Ohba, H. Yanai, H. Negishi, T. Mizutani, A. Takaoka, C. Taya, and T. Taniguchi. 2005. Spatiotemporal regulation of MyD88-IRF-7 signalling for robust type-I interferon induction. Nature 434: 1035-1040.
43. Sun, L., J. Wu, F. Du, X. Chen, and Z. J. Chen. 2013. Cyclic GMP-AMP synthase is a cytosolic DNA sensor that activates the type I interferon pathway. Science 339: 786-791.
44. Kalams, S. A., S. Parker, X. Jin, M. Elizaga, B. Metch, M. Wang, J. Hural, M. Lubeck, J. Eldridge, M. Cardinali, et al; NIAID HIV Vaccine Trials Network. 2012. Safety and immunogenicity of an HIV-1 gag DNA vaccine with or without IL-12 and/or IL-15 plasmid cytokine adjuvant in healthy, HIV-1 uninfected adults. PLoS One 7: e29231.
45. Kim, J. J., K. A. Simbiri, J. I. Sin, K. Dang, J. Oh, T. Dentchev, D. Lee, L. K. Nottingham, A. A. Chalian, D. McCallus, et al. 1999. Cytokine molecular adjuvants modulate immune responses induced by DNA vaccine constructs for HIV-1 and SIV. J. Interferon Cytokine Res. 19: 77-84.